Voriconazole Therapeutic Drug Monitoring is Necessary for Children with Invasive Fungal Infection
![]() |
Kang, Hyun Mi
(Department of Pediatrics, Seoul National University Children's Hospital)
Kang, Soo Young (Department of Pediatrics, Seoul National University Children's Hospital) Cho, Eun Young (Department of Pediatrics, Seoul National University Children's Hospital) Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine) Lee, Ji Won (Department of Pediatrics, Seoul National University Children's Hospital) Kang, Hyoung Jin (Department of Pediatrics, Seoul National University Children's Hospital) Park, Kyung Duk (Department of Pediatrics, Seoul National University Children's Hospital) Shin, Hee Young (Department of Pediatrics, Seoul National University Children's Hospital) Ahn, Hyo Seop (Department of Pediatrics, Seoul National University Bundang Hospital) Lee, Hyunju (Department of Pediatrics, Seoul National University Bundang Hospital) Choi, Eun Hwa (Department of Pediatrics, Seoul National University Children's Hospital) Lee, Hoan Jong (Department of Pediatrics, Seoul National University Children's Hospital) |
1 | Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008;47:674-83. DOI ScienceOn |
2 | Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010;50:27-36. DOI ScienceOn |
3 | National Cancer Institute; March 20, 2013 [cited 2013 July 05]. 4.0:[Available from: http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm]. |
4 | Taketomo CK, Hodding, JH, Kraus DM. Pediatric Dosage Handbook, 16th ed. Hudson, Ohio, Lexi-Comp, Inc.; 2009:1274-6. |
5 | Singh N. Treatment of opportunistic mycoses: how long is long enough? Lancet Infect Dis 2003;3:703-8. DOI ScienceOn |
6 | Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55:1080-7. DOI ScienceOn |
7 | Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011;55:4782-8. DOI ScienceOn |
8 | Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15. DOI ScienceOn |
9 | Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:S3-S14. DOI ScienceOn |
10 | Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-S39. DOI ScienceOn |
11 | Kauffman CA. The changing landscape of invasive fungal infections: epidemiology, diagnosis, and pharmacologic options. Clin Infect Dis 2006;43:S1-S2. |
12 | Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53. DOI ScienceOn |
13 | Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-72. DOI ScienceOn |
14 | Lat A, Thompson III GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011;4:43. |
15 | Levin M-D, den Hollander JG, van der Holt B, Rijnders BJ, Van Vliet M, Sonneveld P, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007;60:1104-7. DOI ScienceOn |
16 | Soler-Palacin P, Frick MA, Martin-Nalda A, Lanaspa M, Pou L, Rosello E, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 2012;67:700-6. DOI |
17 | Imhof A, Schaer DJ, Schwarz U, Schanz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Int J Infect Dis 2006;10:S61. DOI ScienceOn |
18 | den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie S, Levin M-D. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006;57:1248-50. DOI ScienceOn |
19 | Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer 2013;60:82-7. DOI ScienceOn |
20 | Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592-9. DOI |
21 | Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010;54:3225-32. DOI ScienceOn |
22 | Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003;18:48-70. DOI ScienceOn |
23 | Solis-Munoz P, Lopez JC, Bernal W, Willars C, Verma A, Heneghan MA, et al. Voriconazole hepatotoxicity in severe liver dysfunction. J Infect 2013;66:80-6. DOI ScienceOn |
24 | Kim M, Youn H, Kim SB, Cho YH, Lee M, Cho S, et al. A case of visual and auditory hallucinations during intravenous voriconazole therapy. Infect Chemother 2011;43:421-4. DOI |
25 | Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010;54:4116-23. DOI ScienceOn |
26 | Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. DOI ScienceOn |
27 | De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21. DOI ScienceOn |
28 | Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. DOI ScienceOn |
![]() |